Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO) in a research report sent to investors on Friday morning. The brokerage issued a sell rating on the medical research company’s stock.

Organovo Stock Performance

Shares of NASDAQ ONVO opened at $2.12 on Friday. The business’s 50-day simple moving average is $4.70 and its 200-day simple moving average is $4.94. Organovo has a 52 week low of $1.96 and a 52 week high of $21.96. The firm has a market cap of $3.61 million, a price-to-earnings ratio of -2.49 and a beta of 1.13.

Organovo (NASDAQ:ONVO) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($2.28) EPS for the quarter, beating the consensus estimate of ($2.52) by $0.24. Organovo had a negative return on equity of 346.26% and a negative net margin of 10,151.64%. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.05 million. As a group, equities research analysts forecast that Organovo will post -0.77 earnings per share for the current year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.